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Blood coagulation is a finely regulated physiological process
culminating with the factor Xa (FXa)-mediated conversion of
the prothrombin (ProT) zymogen to active-thrombin (T). In
the prothrombinase complex on the platelet surface, FXa
cleaves ProT at Arg-271, generating the inactive precursor pre-
thrombin-2 (Pre2), which is further attacked at Arg-320–Ile-
321 to yield mature T.Whereas the mechanism of physiologi-
cal ProT activation has been elucidated in great detail, little is
known about the role of bacterial proteases, possibly released in
the bloodstream during infection, in inducing blood coagula-
tion by direct proteolytic ProT activation. This knowledge gap is
particularly concerning, as bacterial infections are frequently
complicated by severe coagulopathies. Here, we show that addi-
tion of subtilisin (50 nM to 2 M), a serine protease secreted by
the non-pathogenic bacterium Bacillus subtilis, induces plasma
clotting by proteolytically converting ProT into active Pre2, a
nicked Pre2 derivative with a single cleaved Ala-470–Asn-471
bond. Notably, we found that this non-canonical cleavage at
Ala-470–Asn-471 is instrumental for the onset of catalysis in
Pre2, which was, however, reduced about 100–200-fold com-
pared with T. Of note, Pre2 could generate fibrin clots from
fibrinogen, either in solution or in blood plasma, and could
aggregate human platelets, either isolated or in whole blood.
Our findings demonstrate that alternative cleavage of ProT by
proteases, even by those secreted by non-virulent bacteria such
as B. subtilis, can shift the delicate procoagulant–anticoagulant
equilibrium toward thrombosis.
Blood coagulation is a finely regulated physiological process
that culminates with the factor Xa-mediated conversion of the
prothrombin (ProT)3 zymogen to the active -thrombin (T)
enzyme,which in turn is responsible for the generation of insol-
uble fibrin and activation of platelets via the GpIb–PAR1
pathway (1, 2). ProT (72 kDa) is a vitamin K-dependent gly-
coprotein produced in the liver and circulating at a relatively
high plasma concentration (0.1 mg/ml) (3). The domain archi-
tecture of ProT includes a Gla domain (residues 1–46), a krin-
gle-1 (residues 65–143) and a kringle-2 (residues 170–248)
domain, and a chymotrypsin-like protease domain (residues
285–579) connected by three intervening linker regions (Lnk-1,
-2, and -3) (4). Isolated factor Xa (FXa) has low intrinsic ProT-
converting activity, but when it is assembled in the presence of
Ca2 with cofactor Va in the prothrombinase complex on the
platelet surface, its ability to activate ProT is increased by about
5 orders of magnitude (5). FXa cleaves ProT in a concerted
manner at two sites, i.e. Arg-271 and Arg-320, but the order of
peptide bond cleavage is highly context-dependent. On the
platelet surface, FXa first cleaves ProT at Arg-271 generating
the inactive precursor prethrombin-2 (Pre2), which is attacked
by FXa at Arg-320 to generate the active T species, formed by
the polypeptide chains Thr-272–Arg-320 and Ile-321–Glu-579
(6). The N-terminal chain undergoes further autoproteolytic
cleavage at Arg-284–Thr-285 to yield the mature T. At vari-
ance, on themembrane of red blood cells, FXa first cleaves ProT
at Arg-320, generating the catalytically active meizothrombin,
and then at Arg-271 to generate thematureT (7). Notably,T
is formed by the A-chain (residues 285–320) and the B-chain
(residues 321–579), connected by the disulfide bridge Cys-
293–Cys-439, and differs from the immediate zymogen Pre2
only in the cleaved Arg-320–Ile-321 bond and for the absence
of the fraying N-terminal segment Thr-272–Arg-284 (8).
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It is widely accepted that the route to ProT activation follows
the classical mechanism of trypsinogen activation established
earlier by the seminal work of Bode and Huber (9), whereby
cleavage of the Arg-320–Ile-321 allows the formation of a crit-
ical salt bridge between the positive N-ammonium group of
the newly generated Ile-321–Val-322 segment and the negative
side chain of Asp-524. This electrostatic coupling triggers a
large conformational change leading to the formation/stabili-
zation of the substrate-binding sites and oxyanion hole
required for catalysis. According to the model, the effect of salt
bridging ismainly conformational (10), as the zymogen exists in
unfavorable conformational equilibrium between inactive (E*)
and active (E) forms, and Ile-321–Asp-524 salt bridge forma-
tion is thought to stabilize the active E form (11). For the differ-
ent zymogens, the pre-existing E7 E* equilibrium is variably
shifted to the E* form with equilibrium constants (Keq) ranging
from 108 (trypsinogen) (12) to 7 (tissue plasminogen activator)
(13). For Pre2, aKeq of 10 has been recently determined (14). An
indirect, albeit stringent, proof of the existence of the E7 E*
equilibrium in ProT is that protein binding to thrombin precur-
sors can effectively stabilize the active E form, as demonstrated
in the case of staphylocoagulase (SC) (15) and von Willebrand
factor-binding protein (vWbp) (10), two proteins secreted from
the virulent Gram-positive bacterium Staphylococcus aureus
exploiting a molecular mimicry mechanism to orient their
N-terminal Ile-1–Val-2 dipeptide into the Asp-524 cavity, thus
leading to non-proteolytic activation of ProT.
Proteolytic conversion of ProT to meizothrombin or T can
be also performed by exogenous non-physiological activators,
such as serine and metallo-proteases present in snake venom
(16) or secreted by bacterial cells (17–21). The best character-
ized proteolytic activator of this group is ecarin, a zinc protease
isolated from the venom of the viper Echis carinatus, which
cleaves ProT at the same peptide bond as FXa, i.e.Arg-320–Ile-
321, generating meizothrombin which is ultimately converted
to T after autolysis at Arg-284 (16), thus resulting in systemic
thrombus formation.Nonetheless, little is knownabout the role
that bacterial proteases, possibly released in the bloodstream
during infection, might play in inducing blood coagulation by
directly activating ProT via proteolysis. This issue is particu-
larly important as sepsis, caused by either Gram-positive and
Gram-negative bacteria, is frequently complicated by coagu-
lopathies and, in about one-third of these cases, by dissemi-
nated intravascular coagulation, a hypercoagulable state often
leading to multiple organ failure and death (22).
In this study, we describe the results of experiments designed
to investigate the ability of subtilisin to proteolytically activate
ProT and trigger fibrin generation and platelet aggregation.
Subtilisin (EC 3.4.21.14) (23) is a serine protease (27.3 kDa)
secreted by Bacillus subtilis, a facultative aerobe Gram-positive
bacterium that is found in the gastrointestinal tract of humans,
lacks obvious pathogenicity (24), and becomes virulent only in
immunodeficient subjects (25). Subtilisin is the prototype
member of the subtilase family, the second largest family of
serine proteases (after the chymotrypsin clan) identified to
date, and known members (either pathogenic or non-patho-
genic) span across eubacteria, archaebacteria, eukaryotes, and
viruses (26). Subtilisins exhibit broad substrate specificity, with
a preference to cleave after hydrophobic residues, even though
cleavage at basic amino acids is not rare (27). Our results show
that addition of subtilisin (50 nM to 2 M) to whole blood sam-
ples is able to bypass the coagulation cascade and induce blood
clot formation by directly activating ProT through zymogen
cleavage at Arg-271–Thr-272 and Ala-470–Asn-471 peptide
bonds. The resulting thrombin-like species, hereafter denoted
asPre2, is able to proteolytically convert fibrinogen into fibrin
and to aggregate platelets. Notably, the rise of thrombin-
like activity is caused by the alternative cleavage at the Ala-
470–Asn-471 bond and subsequent formation of theAsn-471–
Asp-524 intramolecular salt bridge. These findings establish a
new paradigm for the proteolytic activation of ProT. Further-
more, our data widen the current notion that bacterial infec-
tions are positively correlated to thrombotic risk and suggest
that even non-virulent bacteria, such as B. subtilis, can shift
the delicate procoagulant–anticoagulant equilibrium toward
thrombosis.
Results
Limited proteolysis of ProT by subtilisin
The data in Fig. 1A indicate that addition of an aliquot of the
proteolysis mixture of ProT with subtilisin to a solution of
theT-specific chromogenic substrate S2238 (28) results in the
release of pNA, as documented by the absorbance increase at
405 nm (A405). The initial rate (v0) of S2238 hydrolysis
strongly increases with the incubation time of ProT with sub-
tilisin, reaching a maximum after 3–5 h and then slightly
decreasing at longer reaction times (Fig. 1B). Notably, under
identical experimental conditions, subtilisin did not cleave
S2238. These results provide clear-cut evidence that cleavage of
ProT zymogen by subtilisin generates thrombin-like species
displaying significant catalytic activity. To identify the subtili-
sin cleavage sites on ProT, non-reducing SDS-PAGE analysis of
the proteolysis reaction was conducted at 37 °C in the 1–300-
min time range (Fig. 2A). The protein bands were electrotrans-
ferred onto Immobilon membrane and sequenced by auto-
mated N-terminal Edman degradation. Alternatively, the gel
bands were excised, in situ digested with trypsin, and subjected
to peptidemass fingerprint analysis by high-resolution LC-MS/
MS. Using a different approach, the proteolysis mixture was
analyzed by RP-HPLC, and the fractions were characterized by
MS/MS (Fig. 2B). The results of these chemical analyses are
summarized in Table 1 and schematically reported in Fig. 3A.
Under limited proteolysis conditions (subtilisin/ProT ratio
of 1:2000 w/w) at 37 °C, subtilisin rapidly attacked ProT,
migrating in non-reducing SDS-PAGE (4–12% acrylamide)
with an apparent molecular mass of about 72 kDa (Fig. 2A).
ProT was (almost) completely degraded after a 10-min reac-
tion, and four major bands were generated at 55, 35, 25, and 12
kDa. The 55-kDa band corresponds to fragmentMet-152–Glu-
579(247) and is generated by cleavage at Ala-151–Met-152
bond in the linker-1 region, i.e. the cleavage site-1 (CS-1) (Fig.
3). Of note, the numbers in parentheses refer to the T
sequence numbering. This fragment contains the K2 and Pre2
domain, and therefore it is equivalent to prethrombin-1 (Pre1),
Ser-156–Glu-579(247), an intermediate resulting from the
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cleavage of ProT by factor Xa at Arg-155 (29). The 35-kDa band
originates from cleavage of ProT or Pre1 at Arg-271–Thr-272
bond in the linker-2 region, i.e. the cleavage site-2 (CS-2), and
corresponds to the sequence of Pre2, Thr-272–Glu-579(247), a
key physiological intermediate during T generation (6, 29).
Albeit unusual, the cleavage at Arg-271 should not be surpris-
Figure 1. Time-course expression of thrombin-like hydrolytic activity duringproteolysis of ProT (A andB) andPre2 (C andD) by subtilisin.A, ProT (0.1
mg/ml, 350l)was treated in TBS addedwith 5mMCaCl2 at 37 °Cwith subtilisin (0.05g/ml) at anenzyme/ProT ratio of 1:2000 (w/w). At increasing timepoints,
an aliquot (28 l) of the proteolysis mixture was added to a solution of the chromogenic substrate S2238 (20 M) in HBS. The time-course release of pNAwas
monitored at 37 °C by recording the absorbance increase at 405 nm. The slope of the straight lines was taken as the initial velocity, v0, of S2238 hydrolysis by
theactive thrombin-like species.B,F, plot of v0 as a functionof the reaction timeofProTwith subtilisin at 37 °C.E, controlmeasurementswereas follows: S2238
(20M) was incubated at 37 °C with subtilisin (0.05g/ml) in the absence of ProT. C, Pre2 was treated under identical experimental conditions as in A. At time
points, aliquots (15l) of the proteolysismixturewere taken and tested for activity on S2238 substrate.D,F, plot of v0 as a function of the reaction time of Pre2
with subtilisin at 37 °C.E, control measurements were carried out as in A. The fitting curves are only intended to help the reader to follow the data points.
Figure 2. Time-course analysis of the proteolysis reaction of ProT by subtilisin. A, non-reducing electrophoretic analysis of the time-course reaction of
ProT (0.1 mg/ml) with subtilisin (0.05 g/ml) at 37 °C. At time points, aliquots (100 l, 10 g) of the proteolysis mixtures were precipitated with cold TCA,
analyzed by SDS-PAGE (4–12%acrylamide), and Coomassie stained. std, molecular weight protein standards. B, RP-HPLC analysis of the proteolysis reaction of
ProTwith subtilisin at 37 °C after a 1-min (black line) and a 10-min (blue line) reaction. Aliquots (20g) of the reactionmixtureswere loaded onto a C4 analytical
column, eluted with an aqueous acetonitrile, 0.1% TFA gradient (dashed line). The chemical identity of material eluted in correspondence of the major peaks
was established by high-resolution MS, and mass values are reported in Table 1.
Non-canonical proteolytic activation of prothrombin
J. Biol. Chem. (2017) 292(37) 15161–15179 15163
ing. Subtilisin, indeed, has a preference for large uncharged res-
idues at the primary specificity site (P1), but hydrolysis at pep-
tide bonds containing Lys or Arg at P1 are also frequent (27).
The two bands at 25- and 12-kDa result from the cleavage at the
peptide bond Ala-470(149a)–Asn-471(149b) in the 148-loop of
Pre2, denoted as cleavage site-3 (CS-3) (Fig. 3). Specifically, the
25-kDa band corresponds to the N-terminal fragment Thr-
272–Ala-470(149a) of Pre2, denoted as NT, whereas the
12-kDa band corresponds to the C-terminal fragment Asn-
471(149b)–Glu-579(247), denoted as CT (Fig. 3A and Table 1).
RP-HPLC andMS analysis of the same proteolysis reaction (10
min at 37 °C) (Fig. 2B and Table 1) confirmed the chemical
identity of the proteolytic fragments reported by SDS-PAGE
and allowed us to identify the presence of minor transient spe-
cies that are further degraded by subtilisin at longer reaction
times, i.e. K2-NT (38,298.4 atomic mass units), F1 (21,732.6
atomic mass units), and K2 (13,093.5 atomic mass units).
Whereas K2-NT and F1 appeared as distinct bands in the SDS-
PAGE, K2 likely co-migrated with CT (12,348.4 atomic mass
units), as their molecular weight differs by only 5%. Notably,
when electrophoresis was run on a 14% acrylamide gel, which
better resolves low-molecular weight species, K2 and CT bands
could be separated (supplemental Fig. S2).Noteworthy,NT and
CT fragments are quite resistant to further proteolysis and
accumulate at longer reaction times (up to 5 h), whereas other
ProT segments, once formed, are rapidly degraded to small
fragments not visible in the electrophoresis gel (Fig. 2A).
Despite the broad specificity of subtilisin (27) and the large
number of potential cleavage sites in the ProT sequence, under
controlled proteolysis, the protease attacks the zymogen at only
three sites, i.e. CS-1, CS-2, and CS-3 (Fig. 3, A and B). The
unique susceptibility of ProT to subtilisin can be explained on
the basis of the zymogen structure (Fig. 3B) (4) and the general
structural requirements for limited proteolysis. Peptide bond
cleavage, indeed, is only partially dictated by sequence and
accessibility properties of the cleavage sites and, to a much
greater extent, by their conformational flexibility (30). Notably,
the subtilisin cleavage sites in ProT perfectly match with the
regions of highest segmental flexibility of the zymogen, as
deduced from theB-factor plot of the crystallographic structure
in the solid state (4) and single-molecule FRET studies in solu-
tion (Fig. 3C) (31). In particular, CS-1 and CS-2 are embedded
in the highly dynamic inter-domain linker regions, whereas
CS-3 is in the highly flexible 148-loop of the Pre2 domain (Fig.
3) (4, 32), corresponding to the autolysis loop in the mature T
(33). Of note, the structure of ProT we used here is that of the
zymogen deletion mutant, ProT(154–167), solved at 2.2-Å
resolution and lacking 14 amino acids in the linker-2 region,
while retaining the conformational properties of the wild-type
ProT in the extended conformation (29, 31). A key aspect that
emerges by comparing the time-course increase of hydrolytic
activity at 37 °C (Fig. 1B) with the progression of the proteolysis
reaction (Fig. 2A) is that cleavage of Pre2 at CS-3 is instrumen-
tal for the onset and increase of thrombin-like hydrolytic
activity.
Limited proteolysis of rPre2 by subtilisin
To investigate the kinetics of proteolytic zymogen activation
by subtilisin solely at the CS-3 site, we performed limited pro-
teolysis experiments on the smallest inactive T precursor,
Pre2. Recombinant human Pre2 (rPre2) was expressed in Esch-
erichia coli, subjected to disulfide oxidative renaturation, and
purified to homogeneity by heparin-Sepharose affinity chroma-
tography, as described (34, 35). Limited proteolysis reaction of
rPre2 was carried out under experimental conditions identical
to those used for ProT.The rate of S2238 hydrolysis (v0) at 37 °C
Table 1
Mass values of the protein fragments generated by limited proteolysis of ProT with subtilisina
a Proteolysis was conducted at 37 °C in TBS, pH 7.4, 5 mM CaCl2. After a 10-min reaction, the proteolysis mixture was fractionated by RP-HPLC (Fig. 2B), and the peptide
material was analyzed by high-resolution MS.
b The theoretical mass values are reported in parentheses, and the error on mass determination was always lower than 60 ppm.
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strongly increased in the 0–90-min time range and then
decreased at longer reaction times, likely because of further
proteolytic degradation (Fig. 1, C and D).
Cleavage of Pre2 by subtilisin was monitored by non-reduc-
ing SDS-PAGE (Fig. 4, A–D) and RP-HPLC (Fig. 4F) in the
temperature range 5–37 °C. Non-glycosylated, intact rPre2
migrates as a 33-kDa band, and in all trials two major bands
were generated at 22 and 13 kDa (Fig. 4, A–D). These bands
were identified by automated Edman sequencing of the electro-
blotted gel bands or by in situ trypsin digestion of the gel bands
followed by LC-MS/MS analysis of the tryptic fragments. As
already established with ProT (see Fig. 2), these fragments
correspond to the non-glycosylated NT and CT fragments of
Pre2, respectively, resulting from specific cleavage at the Ala-
470(149a)–Asn-471(149b) bond, in the region of highest seg-
mentmobility of Pre2 (32). Comparison of the proteolysis reac-
tions of ProT (Fig. 2A) and rPre2 (Fig. 4A), both carried out at
37 °C, reveals that the rate of Pre2 degradation is significantly
higher compared with ProT and that the resulting NT and CT
fragments from rPre2 are less stable to further proteolysis. This
Figure 3. Schematic representation of the subtilisin CS on ProT. A, domain architecture of ProT. The numbers identify the N- and C-terminal ends of the
zymogen domains, according to the ProT sequence numbering: Gla, -carboxyglutamic acid-rich domain; K1, kringle-1 domain; K2, kringle-2 domain; Pre2,
prethrombin-2 domain;NT and CT are theN- and C-terminal fragments of Pre2 derived from cleavage of Pre2 by subtilisin. Non-physiological cleavage sites by
subtilisin are on the top side of the ProT sequence, whereas physiological cleavage sites by factor Xa are on the bottom side. B, ribbon drawing of the structure
of ProT deletion mutant des(154–167), ProT(154–167) (Protein Data Bank code 5edm) lacking 14 amino acids in the linker-2 region connecting K1 and K2
domains (4). Dashed lines represent unresolved linker regions in the X-ray structure. The cleavage sites are indicated by arrows, whereas SS bonds in Pre2
domain are in yellow. The amino acids forming the active site (A.S.) are in blue. C, B-factor flexibility plot of ProT(154–167). The minor cleavage at CS-4 is
indicated by a thinner arrow. Sequences marked in red and identified with small letters (a and b) correspond to those regions in ProT(154–167) which, albeit
displaying substantial conformational flexibility, are not cleaved by subtilisin. Segment a encompasses the sequence Ala-197–His-205, which is embedded in
a short -helical secondary structure in the zymogen and therefore is expected to be protected from proteolysis (30). Segment b spans the sequence
512PDEGKRGD519, contributing to the Na-binding site in mature T. It is highly charged, and for this reason it does not meet the substrate specificity
requirements for subtilisin cleavage (26, 27). Protein structures were visualized with the ViewerPro 4.2 software (Accelerys Inc.), and the B-factor plot was
generated using the What-If software (76).
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difference can be accounted for by the following: (i) the lower
number of subtilisin cleavages sites present on Pre2 structure
compared with ProT; (ii) the lack of glycosylation at Asn-60g
that in the natural glycosylated ProT is expected protect the
zymogen from subtilisin cleavage (30); and (iii) the possible
shielding of the 148-loop operated by theN-terminal F1 region,
which in the solution structure of ProT has been proposed to
fold back on the Pre2 domain (31).
As expected, the cleavage rate decreased at temperatures
37 °C, whereas the specificity of peptide bond cleavage by
subtilisin significantly increased, such that at 10 or 5 °C the
protease hydrolyzed Pre2 virtually at the most flexible site, i.e.
the Ala-149a–Asn-149b bond. Only at longer reaction times
was a very minor band progressively generated, corresponding
to the nicked NT* species, resulting from hydrolysis of the pep-
tide bond Tyr-14j–Ile-14k in the fraying N-terminal region of
Pre2 (Table 1). At each time point, the residual amount of intact
Pre2was estimated by densitometric analysis of the electropho-
retic bands (Fig. 4E), and a specificity constant (kcat/Km) for the
hydrolysis of the Ala-149a–Asn-149b bond at 37 °C was esti-
mated as 0.18 0.02 M1s1. Interestingly, when proteoly-
sis of rPre2 at 37 °C was monitored by RP-HPLC, identical
results were obtained (kcat/Km 0.20 0.02 M1s1) (Fig.
4, F and G).
Purification ofPre2
Tominimize the presence of residual uncleaved Pre2, prote-
olysis of ProT with subtilisin was carried out for 24 h at 10 °C.
Taking advantage of the heparin-binding properties of throm-
bin exosite-II, the proteolysis mixture was fractionated by hep-
arin-Sepharose affinity chromatography (Fig. 5A). The frac-
tionswere analyzed by non-reducing SDS-PAGE (Fig. 5A, inset)
and chemically characterized by LC-MS/MS. The material
eluting as a single chromatographic peak at 0.75 M NaCl (i.e.
fraction F3) split into two bands at 25 and 12 kDa in non-reduc-
ing SDS-PAGE. These bands were identified as the NT and CT
fragments of Pre2. The unretained material (i.e. fractions F1
and F2) contained only short peptides (Fig. 5A, inset), not visi-
ble in the SDS-PAGE, and was derived from further proteolytic
degradation of K1 and K2 domains. Only the material eluting
with F3, but not that eluting in correspondence of F1 or F2, was
able to release pNA from S2238 (Fig. 5B). Furthermore, the
hydrolytic activity of F3 remained constant even after a 24-h
storage at 4 °C (Fig. 5B). Altogether, these results provide evi-
dence that hydrolysis of ProT by subtilisin ends up with the
generation of a stable and functional complex (hereafter
denoted as Pre2) that is formed by the NT and CT fragments
and is held together by non-covalent forces (Fig. 3, B, and C).
For preparative purposes, Pre2 was also prepared from
recombinant Pre2 incubated for 15 h at 5 °C, using the same
zymogen/protease molar ratio as at 37 °C (data not shown).
Conformational characterization ofPre2
The CD spectrum of T displays low ellipticity values and
two unusual distinct minima at 210 and 228 nm, which are
significantly red-shifted compared with those typical of the
-helix structure (208 and 222 nm) (Fig. 6A). As already
pointed out in our earlier work (36), the peculiar far-UV CD
spectrum of T also results from the spectroscopic contribu-
tion in the far-UV region of the aromatic amino acids and SS
Figure 4. Time-course analysis of the proteolysis reaction of Pre2 by subtilisin. A–D, electrophoretic analysis of the time course reaction of Pre2 (2.8 M)
with subtilisin (1.8 nM). In all experiments, Pre2 (0.1 mg/ml) was reacted at the indicated temperatures in TBS, containing 5 mM CaCl2, with subtilisin at an
enzyme/Pre2 ratio of 1:2000 (w/w). At time points, aliquots (50 l, 5 g) of the proteolysis mixtures were precipitated with cold TCA, analyzed by SDS-PAGE
(4–14% acrylamide) under non-reducing conditions, and Coomassie-stained. std, molecular weight protein standards. E, kinetics of the of subtilisin-catalyzed
proteolysis of Pre2, as determined by densitometric analysis of residual intact Pre2 in the gels reported in A–D. The data points were fitted with Equation 1,
yielding kcat/Km values as indicated. F, representative RP-HPLCplots of the proteolysis reaction of Pre2with subtilisin after a 10-min reaction at 37 °C (black line)
and after 90min at 10 °C (blue line). Aliquots (20g) of the reactionmixtures were loaded onto a C4 analytical column, eluted with a linear aqueous, 0.1% TFA
gradient (dashed line). The chemical identity of the protein material eluted from the chromatographic peaks was established by N-terminal sequencing and
LC-MS/MS analysis as follows: Pre2, prethrombin-2; NT, fragment Thr-272–Ala-470; CT, fragment Asn-471–Glu-579; NT*, fragment NT nicked at the peptide
bondTyr-316–Ile-317.G, kinetics of subtilisin-catalyzedproteolysis of Pre2at 37 °CmonitoredbyRP-HPLC. The concentrationof residual intact Pre2atdifferent
reaction times was estimated by integrating the area of the chromatographic peak of Pre2, as in F. After data fitting with Equation 1, the kcat/Km value was
estimated, as reported.
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bonds present in the thrombin sequence (9 Trp, 11 Tyr, 11 Phe,
and 4 cystines) that masks the conformational contribution of
the peptide bond chromophores embedded in secondary struc-
ture elements. Such effects become more important for those
proteins displaying low signal intensity and aremost prominent
in systems where aromatic groups are clustered in the protein
structure (36). The CD spectrum of intact Pre2 (Fig. 6A) differs
from that of mature T by both shape and intensity. These
spectral changes reflect the conformational transition underly-
ing the conversion of Pre2 to T and are likely contributed by
rearrangement of some aromatic amino acids, occurring during
zymogen activation (Fig. 6C). After hydrolysis of the peptide
bond Ala-149a–Asn-149b, the minimum at 226 nm, character-
istic of the intact zymogen, is conserved in the spectrum of
Pre2, whereas the band of Pre2 at 211 nm becomes more
intense and blue-shifted to 208 nm in Pre2. These spectral
changes suggest that proteolysis likely induces (partial) unfold-
ing of the region encompassing the autolysis loop.
At variance with CD, the fluorescence spectrum of Pre2 is
almost superimposable to that of mature T, with a max value
at 334 nm, whereas the emission of Pre2 is remarkably
reduced and red-shifted to 340 nm (Fig. 6B). Both these spectral
features are compatible with the flexibilization and exposure of
some Trp-residues in Pre2 (37), in agreement with the partial
unfolding of Pre2 deduced from CD spectra.
Probing the structure ofPre2 by fluorescence and SPR
bindingmeasurements
The conformation of key regions in Pre2 (i.e. the Na site,
the active-site region, and exosite-1 and -2) was investigated by
site-specific ligand binding, measuring the affinity of ligands
that are known to specifically bind at a given target site (Fig. 7).
The decrease in binding strength, relative to T, was taken as a
strong indication that the conformation of that site was per-
turbed in Pre2.
Na site
The affinity of Na for T and Pre2 was determined by
measuring the change of fluorescence intensity at the emission
max (Fig. 7A). The binding of Na to T leads to an increase of
the fluorescence signal, allowing us to estimate a Kd of 21  3
mM at 25 °C, identical to that reported earlier (38). Conversely,
increasing salt concentrations induced a marked decrease of
the fluorescence intensity in Pre2, along with a reduction of
the affinity for Na by about 20-fold, compared with T. These
results clearly indicate that the Na-binding site in Pre2 is
heavily compromised and suggest that ion binding to Pre2 is
irrelevant at physiological Na concentrations.
Active site
The active-site region was probed by measuring the affinity
of Pre2 and T for inhibitors having different size and affinity
for thrombin and mapping different sub-sites in the protease
catalytic region, i.e. p-aminobenzamidine (PABA), the tripep-
tide (D)-Phe-Pip-Arg-OH (FPR), (D)-Phe-Pro-Arg-chlorom-
ethyl ketone (PPACK), and the hirudin N-terminal domain
1–47 (Hir(1–47)). PABA is a positively charged smallmolecule,
selectively binding toAsp-189,which is located at the bottomof
the primary substrate specificity site S1 of chymotrypsin-like
proteases (39). At variance, FPR extensively penetrates into
thrombin subsites, orienting Arg-3 side chain into the S1 site,
the pipecolyl moiety (Pip2) toward the S2 site (shaped by Tyr-
60a and Trp-60d), and (D)-Phe-1 in the apolar S3 site (formed
by Leu-99, Ile-174, and Trp-215) (33). PPACK, the chlorom-
ethyl ketone analogue of FPR, is the most specific affinity label
for thrombin, such that even small changes in the conformation
of the substrate recognition sites and/or protease catalytic
amino acids dramatically reduces the inhibitory potency (33, 40).
The catalytic Ser-195 O atom in the T active site attacks the
ketone group of the inhibitor to form the hemiketal anion, which
reacts with the nucleophile His-57 N at the chloromethyl group
to release the chloride ion leaving group (33). This results in irre-
Figure 5. Purification and storage stability of Pre2. A, purification of Pre2 by heparin-Sepharose affinity chromatography. For micro-preparative
purposes, a ProT solution (300 g, 0.1 mg/ml) was treated for 24 h at 10 °C with subtilisin (0.05 g/ml) in TBS, added with 5 mM CaCl2. The reaction
mixture was loaded onto a HiTrap (0.7 	 2.5 cm) heparin-Sepharose column, which was equilibrated with TBS and then eluted with a gradient
of NaCl (- - -). The material eluted in correspondence to fractions F1 to F3 (200 l) was precipitated with cold TCA for subsequent electrophoretic and
functional analyses. Inset, SDS-PAGE (4–14% acrylamide) of the fractions eluted from the affinity column, under non-reducing conditions and Coomas-
sie staining. B, hydrolytic activity of the fractions eluted from heparin-Sepharose column. Aliquots (60 l) of F1 (green circle), F2 (blue circle), and F3
(black circle) fractions, as in A, were immediately added to an S2238 solution (20 M) in HBS, and the time course release of pNA was monitored at 37 °C
by recording the absorbance increase at 405 nm. The storage stability of Pre2 was evaluated after incubation of F3 fraction for 24 h at 4 °C (red
circle).
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versible inhibition of T by covalent cross-linking. Hir(1–47) is a
potent and specific inhibitor ofTthat binds to the S2 andS3 sites
and covers the loop regions surrounding the active site, i.e. the
autolysis loop, the 60-loop shaping the S2 site, and the 180- and
220-loop forming the Na-binding site (41, 42).
Whereas the binding of PABA was monitored by measuring
the increase of the ligand quantum yield, the affinity of FPR and
Hir(1–47) was determined by recording the fluorescence
changes that the ligands evoked in Pre2 or T. For PPACK
inhibition, the pseudo-first order association rate constant, kon,
forTandPre2wasdeterminedbymeasuringthetime-depen-
dence decrease in the rate of substrate hydrolysis at a fixed
inhibitor concentration, where kon is the best parameter for
quantifying the potency of covalent inhibition (40, 43).Our data
indicate that Pre2 binds to small reversible inhibitors, i.e.
PABA and FPR, with an affinity identical (1.7-fold) to that of
mature T (Fig. 7, B andC). Likewise, T and Pre2 are irrevers-
ibly inhibited by PPACK with the same association rate constant
(kon1.6–2.0M1s1) (Fig. 7,D andE). Conversely, the affinity
ofPre2 for the larger inhibitorHir(1–47)wasreducedby
6-fold
(Fig. 7F).
From the comparison of inhibitor structures and their binding
mode to thrombin, it emerges that the geometry of the catalytic
site and substrate recognition sites of T are largely conserved in
Pre2, whereas the conformation of the regions surrounding the
protease-active site is perturbed in the nicked species.
Exosite-1 and -2
The conformational state of Pre2 exosites was probed by
exosite-specific binders. Hirugen, i.e. the C-terminal segment
54–65 of hirudin HV1, was used as a safe exosite-I ligand (38),
whereas the C-terminal peptide segment 268–282 of the T
receptor on platelets, glycoprotein Ib (GpIb), was used as a
specific exosite-II binder (44, 45). The affinity of hirugen for
Pre2 decreased by about 9-fold compared with T (Fig. 8A),
suggesting that the structure of exosite-1 in Pre2 is signifi-
cantly perturbed. Contrary to what was observed with mature
T in our recent work (38), incubation ofPre2with saturating
concentrations of hirugen did not enhance the affinity of
the nicked species for Hir(1–47). In fact, a similar Kd value for
the binding of Hir(1–47) to Pre2 was obtained either in the
absence (Kd 0.61 0.10 M) or presence (Kd 0.54 0.14
M) of hirugen.4 This is a clear-cut indication that in Pre2 the
positive allosteric linkage, coupling exosite-1 to the opening of
active site, is essentially lost (46, 47). The affinity ofPre2 orT
for GpIb(268–282) was measured by immobilizing the syn-
thetic peptide biotinyl-PEG-GpIb(268–282) (supplemental
Fig. S1) onto a neutravidin-coated C1 sensor chip (see “Exper-
imental procedures”) and injecting increasing concentrations
of Pre2 or T (Fig. 8B). SPR data in Fig. 8, B–D, indicate that
Pre2 and T share similar affinity for GpIb(268–282), sug-
gesting that T exosite-2 is not significantly altered in the sub-
tilisin-nicked species.
A general trend emerging from the binding measurements is
that different ligands (i.e. Na, FPR, Hir(1–47), and hirugen),
mapping different regions on thrombin, induce similar but
opposite fluorescence changes in Pre2 and T (Figs. 7, A–C
and F, and 8A), whereby all the ligands tested increase the fluo-
rescence intensity of T and, instead, decrease that of Pre2.
This is a clear-cut indication that the conformational changes
induced by ligand binding in Pre2 are intrinsically different
from those triggered inTstructure.Nevertheless, for a correct
interpretation of these results, experimental determination of
Pre2 structure is needed.
Functional characterization ofPre2
Tobetter characterize the substrate specificity ofPre2 com-
pared with mature T, the two species were separately incu-
bated with substrates specific for T (S2238) (28), aPC (S2366)
(48), or factor Xa (S2765) (49). The results in Fig. 9A clearly
indicate that the specificity of Pre2 is qualitatively identical to
that ofT, both cleaving the thrombin-specific substrate S2238
with the highest rate. Michaelis-Menten treatment of S2238
hydrolysis by Pre2 and T reveals that Pre2 hydrolyzes
S2238 with an efficiency (kcat/Km) of 165-fold lower than T,
and importantly, this was mainly due to a selective decrease (by
4 G. Pontarollo, L. Acquasaliente, D. Peterle, I. Artusi, R. Frasson, and V. De
Filippis, unpublished results.
Figure 6. Spectroscopic characterization ofPre2, Pre2, andT. A and B,
far-UV CD (A) and fluorescence (B) spectra of purified Pre2 (red line), Pre2
(blue line), and T. CD spectra were recorded at a protein concentration of 4
M in PBS. Fluorescence spectra were taken at a protein concentration of 30
nM in TBS, pH 8.0, containing 0.2 M ChCl, after exciting the protein samples at
280 nm. The max value ofT and Pre2 (334 nm) is shifted to 340 nm inPre2.
All measurements were carried out at 25 °C, and the resulting spectra were
corrected for the corresponding base lines. C, ribbon drawing superposition
of Pre2 (3sqe, purple) and T (1ppb, orange, red). Relevant amino acids side
chains are colored cyan for Pre2 and yellow forT structure. The approximate
position of relevant thrombin regions are indicated. The aromatic cluster
formedbyTrp-148, Trp-215, Trp-60d, andTyr-60a is evident in the structureof
Pre2 (cyan).
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124-fold) of the catalytic constant (kcat), whereas the Michaelis
constant (Km) was only slightly increased (by 1.4-fold) (Fig. 9B
and Table 2). For T, Km can be approximated to the dissocia-
tion constant (Kd) of the enzyme–substrate complex (50).
Hence, the invariance ofKm strongly suggests that the substrate
specificity sites in Pre2 are fully formed and recognize S2238
with an affinity identical to that of mature T. This conclusion
is fully consistent with the results of fluorescence and enzyme
activity measurements, showing that FPR has the same affinity
forTandPre2 (Fig. 7C) and that PPACK irreversibly inhibits
the two enzymes with the same kon (Fig. 7, D and E). These
findings and the marked decrease of kcat we have measured for
S2238 hydrolysis byPre2 suggest that the catalytic events (fol-
lowing the early binding step) are altered in the nicked species.
However, this should not be surprising. Indeed, although FPR
binding and PPACK inhibition data provide a strong indication
thatPre2 strictly retains the precise stereochemistry and reac-
tivity of the amino acids in the catalytic triad (i.e. His-57, Asp-
102, and Ser-195) of T, these residues belong to physically
distinct (albeit interacting) fragments in Pre2. In particular,
His-57 and Asp-102 are located in the NT fragment, whereas
Ser-195 is in theCT fragment (Fig. 3B). This arrangement could
therefore perturb the optimal coupling of the active-site amino
acids during the catalytic reactions leading to peptide bond hy-
drolysis and product release, with a resulting decrease of kcat.
The catalytic competence of Pre2 was also tested on more
complex substrates, i.e. protein C (PC), fibrinogen (Fb), and
PAR1, by measuring the efficiency of active PC (aPC) genera-
tion in the presence of the cofactor thrombomodulin (TM) (Fig.
9C), fibrinopeptide (FpA and FpB) release (Fig. 9D), and cleav-
age of PAR1(38–60) peptide (Fig. 9E). The corresponding
kinetic parameters are reported in Table 2. Fb and PAR1 both
interact with thrombin at either exosite-1 or the active site (1,
2). At variance, PC binds exclusively to the protease-active site,
andTMaccelerates thrombin-catalyzed PChydrolysis by inter-
acting with T exosite-1 and allosterically modifying the con-
formation of both the protease and zymogen for efficient PC
cleavage (51). Notably, PAR1(38–60) reproduces the substrate
properties of the extracellular domain of PAR1onplatelets, as it
contains both the exosite-1-binding sequence and the scissile
bond Arg-41–Ser-42 for T (52, 53). The efficiency with which
T or Pre2 converts PC zymogen to the active aPC was deter-
mined by a continuous assay, measuring pNA release from the
aPC-specific substrate S2366 (54). Our data indicate that in the
presence of TM Pre2 cleaves PC with an efficiency about 230-
fold lower than T. The kinetics of fibrinopeptide release was
analyzed using Shafer’s model (55), according to which a highly
specific cleavage at the A Fb chain by T leads to the rapid
release of FpA and formation of fibrin I monomers that aggre-
gate to form fibrin I protofibrils. A second cleavage at the B
Figure7.Probing the structureof theNa site (A) andactive site (B–F) ofPre2 (red circle) andT (black circle).A, fluorescencemeasurementsof sodium
binding to Pre2 and T. Samples (15 nM, 1.5 ml) of Pre2 and T in TBS, pH 8.0, containing increasing concentrations of NaCl were excited at 280 nm and
constant temperature (25 0.1 °C). The fluorescence intensity was recorded at the emission max of the proteins, i.e. 334 nm forT and 340 nm forPre2. The
data are expressed as F F0, where F0 is the fluorescence intensity in the absence of NaCl. The data points were interpolated with Equation 2 yielding the Kd
values for Na binding, as indicated. The ionic strength was kept constant at 1 M with ChCl. B, fluorescence binding of PABA to Pre2 and T. Increasing
concentrationsof PABAwereadded toprotein samples (200nM, 1.5ml). Excitationwavelengthwasat 336nm,whereas the fluorescence intensitywas recorded
at 375 nm. Kd values were obtained by fitting the data points to Equation 2, describing the one-site binding model. Fluorescence binding of FPR (C) and
Hir(1–47) (F) toPre2 andT is shown. To a solutionofPre2 orT (100nM, 1.5ml) increasing concentrations of ligandswere added, andprotein sampleswere
excited at 280 nmwith FPR or at 295 nmwith Hir(1–47). The fluorescence intensity was recorded at the emission max of T (334 nm) or Pre2 (340 nm). The
data points relative to the binding of FPR to Pre2 and T and those of Hir(1–47) binding to Pre2 were interpolated with Equation 2, whereas the binding of
Hir(1–47) to T were fitted to Equation 3, describing the tight binding model. D and E, inhibition of T and Pre2 by PPACK. D, progress curves of pNA
generation byT (black lines) andPre2 (red lines) in the absence (dashed lines) and presence (continuous lines) of PPACK. Aliquots (400l) ofT orPre2 stock
solutions were added at 37 °C in HBS, pH 7.4, to a solution of substrate (20 M) and PPACK, as indicated. At each time point, the rate of pNA release (v) was
estimated from the slope of the tangent lines (gray) to the progress curve. E,plot of vt/v0 versus time. The data pointswere interpolatedwith Equation 9 to yield
the values of kobs and kon for PPACK inhibition of T and Pre2.
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chain of fibrin I monomers then leads to the slower release of
FpB and formation of fibrin II protofibrils, which then aggre-
gate to form the fibrin clot. The specificity constants (kcat/Km)
relative to the release of FpA and FpB by Pre2 were deter-
mined as 300- and 100-fold lower, respectively, than thosemea-
sured for T (53). Likewise, the efficiency of PAR1(38–60) hy-
drolysis by Pre2 was reduced by almost 103-fold, compared
with T.
Altogether, the results of ligand binding and enzymatic activ-
ity measurements indicate that although the ligand-binding
properties of T at exosite-2 and the active site are retained in
Pre2, molecular recognition at exosite-1 and Na-site is
Figure8. Probing the structureof exosite-1 (A) and -2 (B–D) ofPre2 (red circle) andT (black circle).A,bindingof hirugen toPre2 andT. Solutions (1.5
ml) of Pre2 (150 nM) or T (50 nM) were added with increasing hirugen concentrations. The protein samples were excited at 280 nm, and the fluorescence
intensity was recorded at the max of the two enzymes, i.e. 334 nm for T and 340 nm for Pre2. The data points were interpolated with Equation 2. All
fluorescence measurements were carried out in HBS at 37 °C. B–D, binding of GpIb(268–282) to Pre2 and T. B, scheme of biotinyl-PEG-GpIb(268–282)
peptide anchoringonto aneutravidin-coatedC1 sensor chip.C,SPR sensograms relative to thebindingofPre2 to immobilizedbiotinyl-PEG-GpIb(268–282).
D, plot of RUmax versus the concentration of Pre2 or T injected in the mobile phase. SPR measurements were carried out at 25 °C in HBS-EP
, and Kd values
were obtained by fitting the data points to Equation 4.
Figure 9. Substrate specificity and catalytic efficiency of Pre2 and T on S2238, protein C, fibrinogen, and PAR1(38–60). A, substrate specificity of
Pre2. Purified Pre2 (red circle) (30 nM, final concentration) was added to solutions of chromogenic substrates (20 M) in HBS at 37 °C, each specific for T
(S2238), aPC (S2366), or factor Xa (S2765), and the release of pNAwas monitored at 405 nm. For comparison, the activity of 100 pM human T (black circle) on
the same substrates is also reported. B, determination of the kinetic constants of S2238 hydrolysis by Pre2. The initial rate of pNA release from S2238 (20M)
by Pre2 (30 nM, red circle) and T (50 pM, black circle) wasmeasured at 37 °C in HBS, 0.1% PEG (200l, final volume). From the interpolation of the data points
with the Michaelis-Menten equation (Equation 5), kcat and Km values were obtained as best-fit parameters (Table 2). C, aPC generation by T (black circle) or
Pre2 (red circle). To a solution of PC (50 nM) in HBS, pH 7.5, 5 mM CaCl2 at 37 °C in the presence of TM (10 nM) and S2366 (40 M) were added aliquots of T or
Pre2, as indicated. The concentration of pNA released from S2366 by aPCwasmonitored at 405 nm in a continuous assay. The resulting progress curveswere
analyzed as in Ref. 54 (continuous lines) to extract the values of kcat/Km relative to PC activation by T or Pre2 (Table 2). D, release of fibrinopeptides A and B
from human fibrinogen. The release of FpA (black and red circles) and FpB (black and red squares) from human fibrinogen (0.35M) by Pre2 (30 nM) (red circle,
red square) or T (0.3 nM) (black circle, black square) was carried out at 37 °C in HBS, and quantified by RP-HPLC (see “Experimental procedures”). Interpolation
of the data points with Equations 6 and 7 yielded the apparent specificity constants (kcat/Km) of FpA and FpB release for Pre2 and T (Table 2). E, cleavage of
PAR1(38–60). The cleavage of PAR1(38–60) peptide (1 M) by Pre2 (10 nM) (red circle) or T (0.1 nM) (black circle) was carried out at 25 °C in HBS. The time
course of PAR1(42–60) fragment release was quantified by RP-HPLC, and the data points were fitted with Equation 8, describing the kinetics of product
formation under pseudo-first order conditions. For clarity, the lower and upper time scale refers to the experiment run with Pre2 (red circle) and T (black
circle), respectively. The estimated kcat/Km values are reported in Table 2.
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reduced by 10- and 20-fold, respectively. Furthermore, the
decrease in the efficiency of substrate hydrolysis is even more
pronounced, especially for those bivalent substrates interacting
with the enzyme at both exosite-1 and the active site, i.e. PAR1
and Fb. However, this is also true for PC activation in the pres-
ence of TM,where the zymogen binds exclusively at the throm-
bin active site while the cofactor tightly binds to exosite-1,
which is compromised in Pre2 (51). Hence, the drop of PC
cleavage by Pre2 is likely the result of the combined effects of
the lower catalytic efficiency of Pre2 and the decreased cofac-
tor activity of TM.
Pre2 induces fibrin generation and platelet aggregation
To address the possible relevance of subtilisin on the onset of
thrombotic events during bacterial infections, we evaluated the
effect of Pre2 on fibrin generation either with purified Fb or
human plasma (Fig. 10A), as well as the ability of subtilisin to
directly generate fibrin in human plasma via Pre2 formation
(Fig. 10B). Finally, the effect of Pre2 on platelet aggregation
was studied either on gel-filtered platelets or in whole blood
(Fig. 10, C and D).
Fibrin generation
The time-course formation of fibrin from purified Fb or
human plasma was monitored by recording the turbidimetric
signal at 350 and 671 nm, respectively (35, 56). The data in Fig.
10A and Table 3 indicate that addition of Pre2 (50 nM) to a
purified Fb solution (0.15 mg/ml, 400 nM) or to diluted (1:2)
human plasma ([Fb] 3.5M) generated similar fibrin clotting
curves converging to an identicalAmax value.However, in blood
plasma, the tc value of Pre2 was prolonged by 1.6-fold com-
paredwith isolated Fb, and themaximal rate of fibrin formation
(Sm) was 4-fold lower. Notably, tc corresponds to the time
necessary for the longitudinal elongation of protofibrils, deriv-
ing from fibrin monomers after removal of fibrinopeptides.
Importantly, the lag phase of fibrin formation by Pre2, either
with purified Fb or human plasma, was 100–200-fold higher
than that estimated with T at the same concentration (50 nM)
(Table 3), reflecting the lower efficiency of fibrinopeptides
release by Pre2 (Fig. 9D). Furthermore, a remarkable (3-
fold) increase of the Amax value was also observed with Pre2
(Amax 0.21), compared with T (Amax 0.08), where Amax is
the maximum turbidity measured when the final fibrin clot is
formed, and it is proportional to the square of the average diam-
eter (d) of the fibers (56). The latter result indicates that the
fibrin network generated by Pre2 is formed by fewer fibers
that, however, are thicker than those produced by the more
catalytically efficient T at the same concentration.
At this point, the question arises as to whether subtilisin
might function like ecarin, inducing the formation in human
plasma of proteolytically active thrombin species that can clot
fibrin. The data in Fig. 10B provide a clear-cut answer to this
question and demonstrate that addition of 0.25 IU of either
Table 2
Substrate specificity ofPre2 and T
The kinetic constants relative to the hydrolysis of thrombin substrates were extracted by interpolating the data points in Fig. 9, as detailed under “Experimental procedures”
and the legend to Fig. 9.
Pre2 T
kcat Km kcat/Km kcat Km kcat/Km
s1 M (M1s1) s1 M M1s1
S2238 0.86 0.04 10.0 1.3 0.09 0.01 106.6 2.2 7.2 0.5 14.8 0.03
kcat/Km (M1s1) kcat/Km (M1s1)
FbpA 0.042 0.001 12.5 0.6
FbpB 0.036 0.008 3.7 0.8
PAR1(38–60) 0.044 0.005 43.3 1.5
kcat/Km (mM1s1) kcat/Km (mM1s1)
PC 0.803 0.012 190.1 5.2
Figure 10. Fibrin generation andplatelet aggregation inducedbyPre2
andT. A, turbidimetric analysis of fibrin generation induced by 50 nMPre2
(dashed lines) or 50 nMT (continuous lines) onpurified fibrinogen (black lines)
or diluted (1:2) humanplasma (red lines). To a human fibrinogen solution (440
nM, 800 l) in HBS at 37 °C, containing 0.1% PEG-8000, was added T (50 nM)
or Pre2 (50 nM), and the time-course generation of fibrin was monitored by
recording the absorbance increase of the solution at 350 nm. With human
plasma samples, the absorbance changewas recorded at 671 nm (right-hand
scale). For clarity, the lower time scale (0–3 min) refers to the experiment run
with T, and the upper time scale (0–150 min) refers to the experiment run
with Pre2. The absorbance scale for both experiments is the same (0–0.25
AU). B, turbidimetric analysis of fibrin generation induced by different con-
centrations of subtilisin (0.25 IU 2 M, red line) (50 nM, blue line) on diluted
(1:2) plasma. Fromeach clotting curve, the values of Sm, tm, tc, andAmaxwere
extracted, as indicated (Table 3 and “Experimental procedures”). C, imped-
ance aggregometry analysis of platelet aggregation induced by Pre2 or T
at 37 °C in WB (blue line) or GFPs (black line). WB from healthy donors (300l;
160,000 platelets/l) was dilutedwithHBS (320l), containingT orPre2 to
a final concentration of 0.5 and 50 nM, respectively. A similar procedure was
usedwithGFP (200.000platelets/l).D,histogramof thenormalizedplatelets
aggregation potency ofPre2 andT expressed as AUC/[E] ratio, where [E] is
themolar enzyme concentration. Each value is the average of single determi-
nations on blood samples from three healthy donors. The error bars corre-
spond to the standard deviation.
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subtilisin (2 M and 50 nM) or ecarin (2.5 nM) to diluted (1:2)
human plasma induced fibrin generation, even with different
time scales. Notably, 4 nM subtilisin was not able to induce
plasma clotting in the time range explored (data not shown). A
clotting time, tc, of 2.1 min was determined for ecarin (see sup-
plemental Fig. S3), in agreement with our previous results (35),
whereas a much longer lag phase was estimated at either 2 M
(tc 2h) or 50 nM subtilisin (tc 14h) (Table 3).Notwithstand-
ing, the clotting curves in Fig. 10B document that even small
subtilisin concentrations (50 nM) are able to clot fibrinogen in
human plasma. The dramatic difference in the plasma clotting
time, observed between subtilisin and ecarin, can be reasonably
accounted for by several factors: (i) the 20-fold lower specificity
constant of subtilisin for CS-3 in Pre2 (kcat/Km  0.18  0.02
M1s1) (Fig. 4, E and G), compared with ecarin (kcat/Km 
4.1 M1s1) (57); (ii) the 100–300-fold lower catalytic effi-
ciency of the resulting nicked Pre2 species to hydrolyze Fb,
compared with T (Fig. 9D); and (iii) the presence of physi-
ological serine proteinase inhibitors in human plasma (e.g.
2-antitrypsin, antiplasmin, and 1-proteinase inhibitor),
which may irreversibly inhibit subtilisin, without affecting
ecarin function (58).
Platelet aggregation
The ability of Pre2 to agglutinate platelets was tested on
whole blood (WB) and gel-filtered platelets (GFP) by multiple
electrode aggregometry (Fig. 10C). This technique measures
the increase of impedance, i.e. the resistance to the passage of
alternate current in a medium between two platinum elec-
trodes, which is caused by sticking activated platelets on the
electrodes (59). Addition of 50 nMPre2 or 0.5 nMT toWB or
GFP yielded comparable aggregation curves, i.e. the time-de-
pendent change of the plasma impedance expressed as relative
aggregation units (AU). Notably, the more intense signal
obtained with both Pre2 and T on GFP reflects the higher
platelets count of GFP (200,000/l) compared with WB
(160,000/l). Integration of AU over time (10 min) gives the
value of the area under the curve (AUC), whereas the ratio
AUC/[E] is taken as the platelet aggregation potency of Pre2
or T, where [E] is the concentration of thrombin-like species.
The histograms in Fig. 10D indicate that the aggregation
potency of Pre2 onWB and GFP is150- and 200-fold lower
than that of T, respectively. The observation that nanomolar
concentrations of Pre2 can still agglutinate platelets is consis-
tent with site-specific binding data showing that peptide bond
nicking does not appreciably perturb exosite-2, which is the
binding site for thrombin on the platelet receptorGpIb (Fig. 8,
B–D). Likewise, the decrease of the aggregation potency is fully
consistent with the marked reduction in the efficiency of
PAR1(38–60) hydrolysis by Pre2 (Fig. 9E).
Molecularmechanism of ProT/Pre2 activation by subtilisin
Our data clearly document that T-like activity appears only
after nicking of Ala-149a–Asn-149b bond and subsequent gen-
eration of a new N-terminal dipeptide segment, i.e. Asn-149b–
Val-149c, on the CT fragment of Pre2. However, the molecu-
lar mechanism linking peptide bond cleavage to catalysis
remains unknown. Notably, in a previous work (36), we used
subtilisin as a probe of the conformational flexibility of the 148-
loop inmature T, in the absence and presence of Na, and we
found the same cleavage site as with ProT and Pre2. To gain
more insights into the mechanism of zymogen activation, T
and Pre2 were subjected to carbamylation of the N termini
with potassium cyanate (KCNO), a reagent that at physiological
pH almost exclusively reacts with theN-terminal-amino groups
of proteins and obliterates the positive charge at the N terminus
(R-NH3) by forminganeutralureidogroup, according to the reac-
tionR-NH2HNCO3R-NHCONH2,whereHNCOis thereac-
tive isocyanicacid inequilibriumwithcyanate (NCO) (60).Nota-
bly, at a given solution pH, the carbamylation rate is positively
correlated with the amount and accessibility of the unprotonated
N-terminal R-NH2 group (61, 62).
At time points, T or Pre2 solutions (1M) were incubated
in the absence or presence of KCNO (0.2 M) at 37 °C, and ali-
quots of these solutions were tested for enzymatic activity on
the S2238 substrate. The data in Fig. 11A indicate that, in the
presence of cyanate, the relative rate of substrate hydrolysis by
either T (100 pM) or Pre2 (50 nM) decreased with time to
different extents. Noteworthy, the reduction of the hydrolysis
rate was stronger with Pre2 than with mature T. After a 1-h
reaction with cyanate, for instance, the activity of T was
reduced by only 10%, whereas that of Pre2 was reduced by

50%. As a control, in the absence of KCNO, the rate of hydro-
lysis remained constantly high. When the effect of cyanate on
TorPre2 functionwas analyzed according to the irreversible
inhibition model, used above for describing PPACK inhibition
(40), a 3-fold higher pseudo-first order inhibition rate constant
(kon) was estimated for Pre2 compared with T (Fig. 11A).
The extent of carbamylation of the N termini in T and Pre2
was estimated by automated Edman sequencing, after a 1-h
reaction with KCNO at 37 °C and subsequent reduction and
carboxamidomethylation of Cys residues (see under “Experi-
mental procedures”). Edman degradation, indeed, starts only if
the terminal N-amino group is available, and thus it allows a
rough estimate of the % ofmolecules in a protein sample having
Table 3
Representative parameters for the fibrin clotting curves generated
with isolated fibrinogenorhumanplasmabyPre2,T, subtilisin, and
ecarin
The parameters of the fibrin clotting curves were extracted from the data reported
in Fig. 10, A and B, and the experimental error was10%.
Sma tmb tcc Amaxd
AUmin1 min min AU
Purified fibrinogene
T (50 nM) 234.0103 0.17 0.06 0.08
Pre2 (50 nM) 15.8103 10.60 6.70 0.21
Human plasmaf
T (50 nM) 8.2103 0.16 0.05 0.08
Pre2 (50 nM) 4.1103 17.10 10.90 0.21
Human plasmaf
Ecarin (2.5 nM) 55.9103 2.40 2.10 0.41
Subtilisin (2 M) 5.2103 125 82.0 0.52
Subtilisin (50 nM) 9.3104 1134 840.0 0.51
a Sm is the value of the maximal slope of the curve.
b tm is the time needed to reach Sm.
c tc is the clotting time and is calculated from the intercept point with the time axis
of the tangent line to the curve at tm.
d Amax is the maximal absorbance change when fibrin generation is complete.
e In fibrin generation measurements, the concentration of purified fibrinogen was
400 nM.
f The estimated concentration of fibrinogen in 1:2 diluted human plasma was 3.5
M.
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free N-terminal ends. Our data indicate that the sequences of
the A-chain in T and that of NT fragment in Pre2 could not
be detected, suggesting that in both enzymes the N-terminal
endwas quantitatively carbamylated and thus fully accessible in
the structure of the two enzymes. Conversely, the B-chain was
almost quantitatively sequenced (
90%), indicating that the
N-terminal Ile-16 in T was deeply buried in the mature pro-
tease structure and thus protected from reaction with cyanate.
At variance, in the case of CT in Pre2, only about 50% of the
fragment molecules could be sequenced, thus suggesting that
the N-terminal Asn-149b was substantially exposed on the
Pre2 structure. These findings are fully consistent with
enzyme activity data showing that the rate constant of Pre2
inactivation by KCNO is 3-fold higher compared with T (Fig.
11A) and indicate that Asn-149b at the N terminus of CT in
Pre2 is, on average, much more exposed than Ile-16 at the
N-terminal end of the B-chain in T.
A key aspect emerging from this work is that the raising of
catalytic competence in Pre2 is not a fortuitous result of flexi-
bilization of the 148-loop in Pre2, occurring after peptide bond
cleavage, but of a precisely concerted conformational change
that is inherently associated with the reactivity of the newly
generated N-terminal Asn-149b. Indeed, neutralization of the
N-terminal positive charge, even with a small-sized carbamyl
group, hinders amidolytic activity of Pre2 (Fig. 11A). As
already established for the zymogens of the trypsin family (9), as
well as for the physiological activation of ProT by FXa (6, 7, 15,
33), it is possible that the new positive N-terminal segment
(Asn-149b–Val-149c), formed after subtilisin cleavage of Pre2,
binds to the negatively charged Asp-194 and triggers a confor-
mational transition very similar to that evoked by the Ile-16–
Val-17 segment, which is generated after FXa cleavage at Arg-
15–Ile-16 bond. Hence, nicking of Pre2 by an endogenous
(FXa) or exogenous (subtilisin) protease, albeit occurring at two
distinct sites on Pre2 structure, can trigger a common physio-
logical mechanism of zymogen activation (Fig. 11B). Visual
inspection of the ProT (5edm) (4) or the Pre2 (3sqe) (32) struc-
ture suggests that this may be actually the case (Fig. 11C), as
both Asn-149b in Pre2 and Ile-16 in T are located in uncon-
strained loop regions, which may become even more flexible
after nicking, and (more importantly) at a comparable distance
(22 Å in T and 16 Å in Pre2) from the critical Asp-194
side chain. The proposed model of Pre2 activation accounts
for the higher rate of carbamylation ofAsn-149b inPre2, com-
pared with that of Ile-16 in T (Fig. 11A). In T structure,
indeed, the NH3 group of Ile-16 is less amenable to react with
cyanate as it is deeply buried in a hydrophobic environment,
where it forms a high-energy salt bridge with the carboxylate of
Asp-194 (33). This salt bridge is likely weaker in Pre2 because
the N-terminal amino group of Asn is 10-fold less basic
(pKa(Asn) 8.72; pKa(Ile) 9.76) (63) and 260-fold less hydro-
phobic than that of Ile (logP(Asn)2.41; logP(Ile)0.03)
(63). The lower stability of the salt bridge between Asn-149b
and Asp-194 is expected to reduce the residence time of Asn-
149b in the Asp-194 cleft and to allow exposure of the N-ter-
minal end, which becomes available for reacting with cyanate
(Fig. 11A). In addition, weakening of the Asn-149b–Asp-194
ionic interaction might also have a direct impact on the cataly-
sis ofPre2, altering the efficiencywithwhich electrostatic per-
turbation of Asp-194 is transmitted long range to the active
site. These considerations may also contribute to explain the
marked decrease of kcat we have measured for Pre2 compared
with T (Fig. 9B).
Discussion
In the early 1900s it was shown that certain bacteria, espe-
cially staphylococci, are able to induce clotting of human blood
(64), and since the late 1930s, fibrin deposition has been recog-
nized as a common feature at the sites of bacterial infection
(65). Very recently, fibrin generation has been proposed as a
host defense mechanism of innate immunity to avoid systemic
activation of coagulation by segregating bacterial pathogens in
a fibrin network at infection sites (66). However, activation of
coagulation can also be seen as a smart evolutionary mecha-
nism, whereby the pathogens exploit the host hemostatic sys-
tem components to escape immune response and prevent their
elimination from the blood by “self-entrapment” within a fibrin
clot (67). Beyond these intriguing host–pathogen evolutionary
Figure11.Mechanismof zymogenactivation inPre2andT.A, effect of
time-course carbamylationofPre2on the rateof S2238 substratehydrolysis.
Time-course hydrolysis of Pre2 (open red circle and solid red circle) and T
(open black circle and solid black circle) in the absence and presence of potas-
sium cyanate. Solutions of Pre2 (1 M) in HBS, pH 7.0, were incubated at
37 °C in the absence (open red circle) and presence (solid red circle) of 0.2 M
KCNO. At the indicated timepoints, aliquots (40l; 50 nM final concentration)
were taken, and the initial rate (vi) of S2238 (20M)hydrolysiswasdetermined
inHBSat 37 °C. For comparison, the activity ofT (100pM, final concentration)
determined in the absence (open black circle) and presence (solid black circle)
of KCNO is also reported. Thedata are expressed as thepercent residual activ-
ity, (vi/v0)	100,where vi and v0 are the rates of hydrolysis determinedat time
ti and 0, respectively. After interpolating the kinetic data with Equation 9,
describing the irreversible enzyme inhibition under pseudo-first order condi-
tions, the corresponding rate constants (kon) were determined for Pre2
(4.8	 102 M1min1) and T (1.6	 102 M1min1). B, schematic repre-
sentation of the physiological and non-physiological Pre2 zymogen activa-
tion by factor Xa or bacterial subtilisin, respectively. After physiological cleav-
age of the peptide bond Arg-15–Ile-16 by FXa in Pre2, the newly generated
dipeptide Ile-16–Val-17, swings into the 194-cleft and triggers substrate-
binding sites and oxyanion hole formation, required for catalysis. Likewise,
after non-physiological cleavage by subtilisin at the peptide bond Ala-149a–
Asn-149b in the exposed -loop of Pre2, the new N-terminal dipeptide Asn-
149b–Val-149c can enter the 194-cleft and evoke zymogen activation. C,
transparent surface representation of Pre2 showing Asp-194 positioned at
the bottom of a deep cleft in ProT structure (Protein Data Bank code 5edm)
shapedby the two-barrels of Pre2. The cleavage sites for FXa (Arg-15–Ile-16)
and subtilisin (Ala-149a–Asn-149b) are also indicated.
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strategies, the pathological activation of coagulation in infec-
tious diseases is associated with high morbidity and mortality
(22, 68). Nonetheless, the molecular mechanisms linking bac-
terial infection to thrombosis have not been fully understood
(69). It is generally accepted that coagulopathic complications
in sepsis are mainly triggered by surface bacterial lipopolysac-
charides (LPS) that interact with Toll-like receptors on mono-
cytes and induce expression of tissue factor, thus activating the
“extrinsic” pathway of thrombin generation (66, 69). Intrigu-
ingly, LPS are present on Gram-negative bacteria, but they are
absent on the surface of Gram-positive bacteria, and infections
from the latter group of pathogens are also frequently compli-
cated by severe coagulopathies (68). These observations indi-
rectly suggest that other factors, different from LPS-induced
activation of blood coagulation, should be considered for
understanding the positive relation existing between sepsis
and thrombosis. Mounting evidence, accumulated in the last
decades, indicates that microbial pathogens can bypass the
coagulation cascade and directly trigger ProT activation either
by proteolytic (17–21) or non-proteolytic mechanisms (10, 15).
Whereas the non-proteolytic mechanism, leading S. aureus
proteins SC and vWbp to conformationally activate ProT, has
been elucidated in great detail (10, 15), notmuch information is
available regarding the mechanisms underlying the proteolytic
conversion of ProT to thrombin-like active species and on the
effect that the ensuing thrombin-like forms have on fibrinogen
cleavage (21), fibrin generation, and platelet aggregation (20).
In addition, when available, literature data indicate that differ-
ent proteases (e.g. serine protease, cysteine protease, or met-
allo-protease) from different bacterial pathogens (e.g. Gram-
positive or Gram-negative bacteria) convergently hydrolyze
ProT at the canonical Arg-320–Ile-321 cleavage site for FXa,
leading to the generation of meizothrombin/desF1-meizo-
thrombin active species or even to the transient generation of
mature T, as in the case of gingipain, an Arg-specific cysteine
protease isolated from the pathogenic agent of periodontitis
Porphyromonas gingivalis (18).
Our results show that addition of subtilisin (50 nM to 2M) is
able to bypass the coagulation cascade and induce plasma clot
formation and aggregate platelets by directly activating ProT
through zymogen cleavage at Ala-151–Met-152 and Arg-271–
Thr-272 peptide bonds and at the non-canonical cleavage site
Ala-470–Asn-471. The resulting Pre2 species proteolytically
converts fibrinogen into fibrin (either in solution or in normal
blood plasma) and aggregate platelets (either isolated or in
whole blood). Pre2 was purified to homogeneity and thor-
oughly characterized in terms of chemical composition and
conformational and functional properties, allowing us to safely
conclude that Pre2 is constituted by NT and CT fragments
forming a stable and functional fragment-complementing sys-
tem, held together only by non-covalent interactions. Notably,
the rise of thrombin-like activity is caused by the alternative
cleavage at the Ala-149a–Asn-149b bond and subsequent for-
mation of the non-canonical Asn-149b–Asp-194 intramolecu-
lar salt bridge. These findings establish a new paradigm for the
proteolytic activation of ProT, whereby nicking of Pre2 domain
at different sites can evoke a common (physiological) mecha-
nism of zymogen activation. The results reported in this work
also indicate that proteases secreted by even non-virulent bac-
teria, such as B. subtilis, can shift the delicate procoagulant–
anticoagulant equilibrium toward thrombosis and pave the
way to further investigate the ability of other subtilisin pro-
teases (70), produced by known pathogenic bacteria (e.g.
Shiga toxigenic E. coli, Streptococcus pyogenes, Pseudomonas
aeruginosa, and Plasmodium falciparum) and sharing high
sequence similarity with subtilisin form B. subtilis, to affect
blood coagulation.
Experimental procedures
Reagents
Human T, ProT, PC, and rabbit TM were purchased from
Haematologic Technologies (Essex Junction, VT). Subtilisin
(EC 3.4.21.62) from B. subtilis, ecarin from Echis carinatus,
human plasma fibrinogen, PABA, TFA, PPACK, and KCNO
were purchased from Sigma. Recombinant human Pre2 was
expressed in E. coli, renatured, and purified as detailed previ-
ously (34, 35), and Twas obtained from Pre2 after ecarin acti-
vation. Sequencing-grade bovine trypsin was from Promega
(Madison, WI). Chromogenic substrates S2238, S2366, and
S2765 were purchased from Chromogenix (Bedford, MA). (D)-
Phe-Pip-Arg-OH (FPR), hirugen 54GDFEEIPEEY*LQ65 (53),
hirudin N-terminal domain 1–47, Hir(1–47) (71), biotinyl-
PEG-GpIb(GDEGDTDLY*DY*Y*PEE (44), where Y* stands
for tyrosine phosphate), and PAR1(38–60) 8LDPR2SFLLRN-
PNDKYEPFWEDDE60 (52) were synthesized in our laboratory
by the solid-phase strategy, using the fluorenylmethyloxycar-
bonyl-chemistry on a PS3 automated synthesizer (Protein
Technologies), purified by RP-HPLC, and chemically charac-
terized by high-resolution mass spectrometry. Reagents for
electrophoresis were from Sigma or Bio-Rad. All other salts,
solvents, and reagents were of analytical grade and purchased
from Sigma or Merck (Darmstadt, Germany).
Limited proteolysis of ProT and Pre2 by subtilisin
ProT or Pre2 (0.1 mg/ml) were reacted with subtilisin (0.05
g/ml) at different temperatures in 5mMTris-HCl, pH7.4, 0.15
MNaCl, 0.1% PEG-8000 (TBS), containing 5mMCaCl2. At time
intervals, aliquots of proteolysis mixtures were taken, and the
protein component was precipitated overnight at 20 °C with
10% ice-cold trichloroacetic acid (TCA) in acetone. After cen-
trifugation, the protein pellet was dissolved with non-reducing
sample loading buffer, sonicated for 10 min, analyzed by non-
reducing SDS-PAGE (4–12% acrylamide), and then Coomass-
ie-stained. Alternatively, aliquots of the proteolysis mixture
were taken and analyzed for hydrolytic activity on the chromo-
genic substrate S2238 (see below). For Pre2, the kinetics of pro-
teolysis was monitored by either non-reducing SDS-PAGE
(4–14% acrylamide) or RP-HPLC. The relative intensity of the
Pre2 gel bands, after Coomassie staining, was estimated by
densitometric analysis, using a Geliance-600 Chem-Imaging
system (PerkinElmer Life Sciences) and ImageJ software. RP-
HPLC analyses were performed on a Grace-Vydac (Columbia,
MD) C4 (4.6 	 150 mm) analytical column, connected to a
Jasco (Tokyo, Japan) 1500HPLC system. The chromatographic
peaks corresponding to intact Pre2 were integrated using the
software Borwin. The densitometric or chromatographic data
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were fitted to Equation 1, describing a pseudo-first order reac-
tion (36),
S	 S0  e
kt (Eq. 1)
where [S0] and [S] are the Pre2 concentrations at the beginning of
the reaction and after time t, respectively, and k is the observed
kinetic constant for hydrolysis, obtained as a fitting param-
eter. Under pseudo-first order conditions, the specificity
constant (s kcat/Km) for the hydrolysis of Pre2 by subtilisin
was derived as s  k/[E], where [E] is the protease
concentration.
Identification of the subtilisin cleavage sites on ProT and Pre2
The cleavage sites were identified by electroblotting the pro-
tein bands, generated from ProT and Pre2, onto an Immobilon
membrane (Merck-Millipore, Billerica, MA) and N-terminal
sequencing on an automated Procise sequencer (Applied Bio-
systems, Foster City, CA). Blotting was performed at 4 °C in 10
mM CAPS, pH 10.5, at 50 V for 3 h. Alternatively, the gel bands
were excised and subjected to in situ peptide mass fingerprint
with trypsin as described (72). After extraction of the tryptic
peptides from the gel, the proteolytic mixture was loaded onto
a Grace-Vydac (Hesperia, CA) C4 (1	 10 mm) microbore col-
umn connected to an Agilent (Santa Clara, CA) 1290 UHPLC
system. The columnwas eluted at a flow rate of 50l/min, with
a linear aqueous acetonitrile, 0.1% formic acid gradient, from15
to 65% in 30 min. The effluent from the column was analyzed
on-line by high-resolution mass spectrometry (MS), with
respect to mass values and amino acid sequence data. Using a
different approach, aliquots of the proteolysis mixture with
subtilisin, conducted at 10 °C in TBS without PEG-8000, were
taken and analyzed by LC-MS to obtain the accurate mass val-
ues of the proteolytic fragments. Analyses were performed in
the positive ionmode, using aWaters (Milford,MO)Xevo-G2S
Q-TOF mass spectrometer and the software programs Mass-
Lynx 4.1 and BioPharmaLynx for data acquisition or analysis.
Purification ofPre2
For micro-preparative purposes, ProT (0.1 mg/ml, 300 g)
was treatedwith subtilisin (0.05g/ml) for 24 h at 10 °C in TBS,
containing 5 mM CaCl2. The reaction mixture was then fraction-
ated on a HiTrap (0.7	 2.5 cm) heparin-Sepharose column (GE
Healthcare,LittleChalfont,UK)equilibratedwithTBS,containing
0.25 MNaCl, and then elutedwith the same buffer, containing 1 M
NaCl. The material eluted in correspondence to the major chro-
matographic peak was collected, stored at 20 °C, and used for
subsequent analyses. The chemical identity and homogeneity
Pre2 was confirmed by non-reducing SDS-PAGE, RP-HPLC,
and high-resolutionMS analysis, as described above.
Spectroscopic characterization ofPre2
Protein concentration was determined by UV absorption at
280 nm on a Jasco V-630 spectrophotometer, using a molar
absorptivity value (280 nmM ) of 67,161 or 66,424 M1cm1 for
commercial and recombinant T, respectively, and 99,360 and
67,871 M1cm1 for ProT or Pre2/Pre2. The active-site con-
centration of T was also determined by titration with hirudin
(42) and found to be identical ( 5%) to that determined spec-
trophotometrically. Far-UV CD spectra were recorded on a
Jasco J-810 spectropolarimeter, equipped with a Peltier tem-
perature control system. The spectra were recorded in a 1-mm
cell, at a scan speed of 10 nm/min, with a response time of 16 s,
and resulted from the average of four accumulations after base-
line subtraction. CD data were expressed as the mean residue
ellipticity [
]  
obsMRW/(10lc), where 
obs is the observed
signal in degrees; MRW is the mean residue weight of recom-
binant T (115.03 Da) and Pre2/Pre2 (114.98 Da); l is the
cuvette pathlength in cm; and c is the protein concentration in
grams/ml. Fluorescence spectra were recorded on a Jasco
FP-6500 spectropolarimeter, equipped with Peltier tempera-
ture control system, in a 1-cm pathlength cuvette (2ml internal
volume) at a scan speed of 200 nm/min using excitation and
emission slits of 5 and 10 nm, respectively. Measurements were
carried out at least in duplicate at 25  0.1 °C, and the spectra
were subtracted for the corresponding baselines.
Fluorescence bindingmeasurements
For measuring the binding of Na, incremental volumes of a
solution containing 15nM recombinantTorPre2 inTBS, pH
8.0, 1 M choline chloride, were withdrawn and then restored
with the corresponding volumes of a solution containing 15 nM
T or Pre2 in TBS, pH 8.0, 1 M NaCl, such that the ionic
strength and enzyme concentration were held constant at 1 M
and 15 nM, respectively, and the Na concentration was
increased (38). Samples were excited at 280 nm (25  0.1 °C),
and the fluorescence intensity was recorded at the max versus
[NaCl]. The equilibrium dissociation constants of PABA
(293 nmM  15	 103 M1cm1), FPR (257 nmM  200 M1cm1),
Hir(1–47) (280 nmM  2920 M1cm1), and hirugen (280 nmM 
418M1cm1) forTorPre2were obtained by adding, under
gentle magnetic stirring (30 s), incremental volumes (2–10 l)
of ligand stock solutions in 20mMHEPES, pH 7.4, 0.15 MNaCl,
0.1% PEG-8000 (w/v) (HBS) to T or Pre2 solutions in the
same buffer. At each ligand concentration, samples were incu-
bated for 2 min at 37 °C and excited at 280 nm, using an exci-
tation/emission slit of 5 and 10 nm. The emission intensity was
recorded at the protein max, after subtracting the correspond-
ing spectra of the ligands alone. Fluorescence data were cor-
rected for sample dilution, which was always2% at the end of
the titration. Photobleaching was almost eliminated, even after
prolonged light exposure, by using a 1-cm pathlength quartz
cuvette (2 ml) with two frosted walls that are able to diffuse the
incident light inside the sample, thus preventing photodegra-
dation of Trp residues. To prevent inner filter effect (IFE), the
optical density of the solution was kept always lower than 0.05
units both at ex and em (38). For PABA binding, samples were
excited at 336 nm, and the emission was recorded at 375 nm,
after baseline subtraction and correction for IFE (35). For all
ligands tested, except Hir(1–47) binding to T, the data points
were interpolated with Equation 2, describing the single-site
binding model (38),
F	 Fmax 
L
Kd L
(Eq. 2)
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In the case of Hir(1–47)-T interaction, fluorescence data
were fitted to Equation 3, describing the tight-binding model
(38),
F	 Fmax 
b b2 4R][L]
2[R]
with b	 R L Kd
(Eq. 3)
where R and L are the total enzyme and ligand concentrations,
respectively, and RL is the enzyme-ligand complex. F and
Fmax are the changes of fluorescence intensity measured at
intermediate or saturating ligand concentrations. The dissoci-
ation constant, Kd, of the complex was obtained as a fitting
parameter.
SPR
SPR measurements were carried out at 25 °C on a dual flow
cell Biacore-X100 instrument (GE Healthcare). A carboxym-
ethylated C1 sensor chip was first derivatized at pH 5.0 with
NeutrAvidin (Pierce). The NeutrAvidin-coated chip was then
loaded for 700 s at a flow rate of 10 l/min with a solution (100
l, 0.4 M) of the synthetic peptide Biotinyl-PEG-GpIb(268–
282). Notably, NeutrAvidin (pI 6.3) was used as an excellent
alternative to avidin (pI  10) for minimizing non-specific
binding (53, 72) Finally, aliquots (100l) of T and Pre2 solu-
tions at increasing concentrations were injected over the Neu-
trAvidin sensor chip saturated with biotinyl-PEG-GpIb(268–
282) (supplemental Fig. S1) at a flow rate of 10 l/min, with a
contact time of 350 s, in 10mMHEPES, pH 7.4, 150mMNaCl, 3
mM EDTA, 0.05% polyoxyethylene sorbitan (HBS-EP). Each
binding curve was subtracted for the corresponding baseline
obtained on the reference flow cell and accounting for non-
specific binding, which was found2% of RUmax. The dissoci-
ation constant (Kd) relative to the binding of T or Pre2 to
immobilized biotinyl-PEG-GpIb(268–282) was obtained as a
fitting parameter by plotting the value of the response units at
the steady state (RUeq) versus T or Pre2 concentration and
interpolating the data points with Equation 4,
RUeq 	 RUmax 
L
Kd L
(Eq. 4)
where L is the concentration of T or Pre2, and RUeq and
RUmax are the response units, measured at the steady state, at
intermediate and saturating [L] (73). The binding data were
analyzed using the BIAevaluation software.
Enzymatic activity assays
Chromogenic substrates—Hydrolytic activity of T and
Pre2 was determined at 37 °C in HBS on the chromogenic
substrates S2238 ((D)-Phe-Pip-Arg-pNA), S2366 (pyro-Glu-
Pro-Arg-pNA), and S2765 (Arg-Gly-Arg-pNA) by measuring
the release of p-nitroaniline (pNA) at 405 nm (405 nmM  9920
M1cm1). The kinetic constants (kcat andKm) for substrate (S)
hydrolysis were determined by the standardMichaelis-Menten
treatment (53) using Equation 5,
v0	
kcat[E][S]
KM S
(Eq. 5)
where E is the enzyme concentration, and v0 is the initial rate of
substrate hydrolysis, calculated when 10% of product was
generated.
Fibrinopeptide release—The kinetics of fibrinopeptide A
(FpA) and B (FpB) release by T or Pre2 was followed as ear-
lier reported (53). Briefly, human fibrinogen (Fb) (280 nmM 
5.1105M1cm1) was desalted on an in-house packed (8	 125
mm) G10 fast-flow column (GE Healthcare) eluted with HBS,
pH 7.4, at a flow rate of 0.3 ml/min. Freshly prepared Fb (0.35
M) was reacted at 37 °C with Pre2 (30 nM) or human T (300
pM), and at fixed time points proteolysis mixtures were added
with formic acid (2% v/v final concentration) to block the pro-
teolysis reaction and induce precipitation of unreacted Fb.
After centrifugation (10,000 	 g for 5 min at 4 °C), the super-
natant (1.0 ml) was withdrawn, lyophilized, dissolved in 6 M
guanidiniumhydrochloride solution (170l), and injected (100
l) onto a RP-HPLC (4.6 	 250 mm) C18 column (Grace-Vy-
dac, Columbia, MD). The column was equilibrated with 40 mM
ammonium phosphate buffer, pH 3.1, and eluted with an ace-
tonitrile gradient. The absorbance of the effluent was recorded
at 205 nm, and the amount of FpA (205 nmM  4.40104
M1cm1) and FpB (205 nmM  5.12104 M1cm1) released
was determined by integrating the area under the chromato-
graphic peaks. A biocompatible Bio-410 HPLC system
(PerkinElmer Life Sciences), connected to a ISS-100 autosam-
pler, was used for all analyses.
The specificity constants, kcat, A/Km, A and kcat, B/Km, B, for the
release of FpA or FpB by T or Pre2 were determined by inter-
polating the data points to Equations 6 and 7, respectively (55),
FpAt	 FpA]  1 e
kt) (Eq. 6)
FpBt	 FpB]  1   e
kt   ekt (Eq. 7)
where [FpA]t or [FpB]t and [FpA]∞ or [FpB]∞ are the concen-
tration of FpA or FpB at time t and∞, respectively, and k and k
are the observed kinetic constants for FpA or FpB release,
obtained as fitting parameters. Under pseudo-first order con-
ditions and low substrate concentration, the specificity con-
stants could be easily determined, kcat, A/Km, A  k/[E] and
kcat, B/Km,B k/[E], where [E] is the protease concentration.
PAR1(38–60) hydrolysis—Hydrolysis of the synthetic pep-
tide PAR1(38–60) (1M) by T (100 pM) or Pre2 (10 nM) was
carried out at 25 °C in HBS. At time points, aliquots (360 l)
were taken, acid-quenched (10 l, 4% aqueous TFA), and
loaded (350 l) onto a Grace-Vydac (4.6 	 250 mm) C18 col-
umn. The column was eluted with a linear acetonitrile, 0.078%
TFA gradient from 10 to 45% in 40 min, and the release of
PAR1(42–60) (205 nmM  95870 M1cm1) (53) was quantified
by integrating the area under the chromatographic peak. The
kinetic data were interpolated with Equation 8, describing a
pseudo-first order reaction,
Pt	 P  1 exp(kobs  t) (Eq. 8)
where [P]∞ is the concentration of the fragment PAR1(42–60)
when the proteolysis reaction was complete, and kobs is the
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observed kinetic constant for PAR1(38–60) hydrolysis, ob-
tained as a fitting parameter. As for the release of fibrinopep-
tides, under pseudo-first order conditions and low substrate
concentration, kcat/Km could be derived as kobs/[E].
Protein C activation—The generation of active PC (aPC) by
T or Pre2 (E) in the presence of thrombomodulin (TM) was
monitored by recording the release of pNA (P) from the sub-
strate S2366 (S), according to the well-established reaction
Scheme 1 (54). The reaction was carried out at 37 °C in HBS,
containing 5 mM CaCl2. The time course of pNA release was
monitored by continuously recording the absorbance increase
at 405 nm, and the progress curves were analyzed as described
(54) to extract the specificity constants (kcat/Km) of PC hydro-
lysis by T or Pre2.
Inhibition of thrombin hydrolytic activity by PPACK—It has
been shown that PPACK (I) rapidly reacts with thrombin (E) to
formanon-covalent encounter complex (EI*), which thenmore
slowly converts to the covalent, non-dissociating complex EI,
according to the reaction Scheme 2, describing a one-step irre-
versible process (40) where kon is the second-order rate con-
stant for the formation of EI. Under pseudo-first order condi-
tions ([I] 

 [E]), the observed rate constant, kobs, can be
extracted from Equation 9 (40, 74),
vt
v0
	
E]t
[E]0
	 exp(kobs  t) (Eq. 9)
where kobs  kon[I]0, whereas vt and v0 are the initial rates of
substrate hydrolysis by the enzyme at a fixed inhibitor concen-
tration, [I]0, at time t and time 0, respectively. Considering that
complete inhibition of both T and Pre2 occurred in a rela-
tively short time range (90–240 s), accurate estimates of vwere
obtained in a continuous assay, from the slope of the tangent
lines to the progress curves of pNA generation at each t value
(i.e. from the first derivative of the progress curve).
Fibrin generation and platelet aggregation
Fibrin generation was started by adding T or Pre2 (50 nM)
to a freshly desalted Fb solution (0.44 M) in HBS at 37 °C,
whereas the time course clot formationwas followed by contin-
uously recording the solution absorbance at 350 nm (i.e. the
turbidity) on a Jasco V-630 spectrophotometer. From the clot-
ting curve, the values of Sm, tm, tc, and Amax were extracted as
described in Fig. 10B and Table 3 (35). When fibrin generation
was induced in humanplasma samples (diluted 1:1withHBS) at
37 °C, the absorbance change was recorded at 671 nm.
Platelet aggregation was determined in whole blood or in
gel-filtered platelets by multiple electrode aggregometry, using
a multiplate analyzer (Dynabyte, Munich, Germany). The area
under the aggregation curve (AUC) was determined over
10-min reaction time. Citrate-treated venous blood samples
were taken from three healthy donors as follows: one male and
two females, 28–35 years of age, and non-smokers. The donors
gave written informed consent for participation in this study,
which was approved by the institutional ethics committee of
the Padua University Hospital. Platelets were isolated by load-
ing platelet-rich plasma (PRP) samples onto a (1.5 	 25 cm)
Sepharose 2B gel-filtration column (GE Healthcare), equili-
brated with HBS, containing 0.2% bovine serum albumin, 5.5
mMglucose, and 5mMKCl. PRPwas prepared by centrifugation
of blood samples (800 rpm for 15 min at 4 °C). Platelet counts
were determined using an automated Hematology Analyzer
XP-300 (Sysmex Co., Kobe, Japan).
N-terminal carbamylation
To assess the susceptibility of the N terminus to chemical
modification by KCNO (0.2 M), Pre2 (1 M) or T (1 M) was
incubated inHBS at 37 °C. In a discontinuous assay, at different
time points the reactions were stopped by dilution, and the
residual amidolytic activity was determined by S2238 hydroly-
sis. Control experiments without KCNO were conducted in
parallel. The relative rate of substrate hydrolysis was plotted as
a function of the reaction time with KCNO, and the data points
were analyzed as reported above for the irreversible thrombin
inhibition by PPACK to obtain the pseudo-first order associa-
tion rate constant kon.
The extent of carbamylation of the N termini in T and
Pre2 was comparatively estimated by automated Edman
sequencing, after a 1-h reaction with KCNO at 37 °C (60). An
identical amount (100 pmol) of purified T A- and B-chain or
Pre2 NT and CT fragments were loaded on a Procise
sequencer (Applied Biosystems). Prior to analysis, these chains/
fragments were subjected to disulfide bond reduction and
carboxamidomethylation with dithiothreitol and iodoacet-
amide (75) and subsequent purification by RP-HPLC. As a ref-
erence, sequence analyses were performed on the correspond-
ing species derived from T and Pre2 samples that were not
treated with KCNO. The area of the chromatographic peak
corresponding to the phenylthiohydantoin-derivative of the
N-terminal amino acid in each untreated species was taken
as the 100% reference value that was used to estimate the %
carbamylation of KCNO-treated samples.
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